Feds approve Regeneron's new eczema drug

Drug developer Regeneron Pharmaceuticals won federal approval Tuesday for its new eczema treatment, which analysts are projecting could lead to more than $3 billion in annual sales. Regeneron (NASDAQ: REGN) and its partner Sanofi received approval from the U.S. Food and Drug Administration for Dupixent. The drug has been described as the first of its kind to treat eczema or atopic dermatitis for patients who do not respond to atopical steroids. The approval comes after the T arrytown, New York,…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news